Symeres has acquired Exemplify BioPharma for an undisclosed price, marking the CRO and CDMO’s second purchase in the U.S. in 2022.
In April, Netherlands-based Symeres snapped up U.S. lipid maker and organic chemistry contractor Organix as part of the company’s efforts to expand its drug discovery business into the lipids market to meet demand from developers of mRNA therapeutics and vaccines. Financial terms of the deal weren’t disclosed.
Next in its sights is Exemplify, which is based in Cranberry, New Jersey, and has 20 employees who provide end-to-end small-molecule chemistry manufacturing and controls services to pharmaceutical and biotech partners. Exemplify also offers services in process chemistry, analytical chemistry and formulation development.
“This acquisition, following the addition of Organix earlier this year and our investment plans for all of our R&D facilities, is a further tangible demonstration of Symeres’ strategy of building a leading mid-sized transatlantic pharmaceutical R&D service provider for our clients around the world,” Symeres CEO Eelco Ebbers, Ph.D., said in the release.